A comprehensive study involving over 18,000 participants has unveiled critical genetic advantages in a unique group known as “SuperAgers.” These individuals, typically aged 80 and older, demonstrate remarkable resistance to dementia, particularly Alzheimer’s disease. Researchers discovered that SuperAgers are significantly less likely to carry the APOE-ε4 gene variant, which is linked to a higher risk of Alzheimer’s, while they are more likely to possess the APOE-ε2 variant, associated with a lower risk.
The research, led by neuropsychologist Leslie Gaynor from Vanderbilt University Medical Center, highlights the importance of genetic factors in exceptional cognitive aging. “This was our most striking finding,” Gaynor remarked. “Our study suggests that the Superager phenotype can be used to identify a particularly exceptional group of oldest-old adults with a reduced genetic risk for Alzheimer’s disease.”
SuperAgers are characterized by exceptional memory capabilities, often comparable to individuals decades younger. Their cognitive sharpness extends beyond memory alone; they are also less likely to develop dementia compared to the general population. This study aims to unravel the underlying mechanisms of dementia and explore potential strategies for delay and mitigation.
Research on genetics has established that the APOE-ε4 variant is the most significant genetic risk factor for Alzheimer’s disease, a progressive neurodegenerative condition typically manifesting in older adults. Conversely, the APOE-ε2 variant provides a protective effect against the disease. Imaging studies have shown differences in brain structure and its resistance to amyloid plaques associated with Alzheimer’s between SuperAgers and the rest of the population.
Gaynor, alongside statistical genetic analyst Alaina Durant and their team, analyzed data from eight extensive aging studies conducted in the United States. The study defined SuperAgers as those aged 80 and above whose cognitive performance exceeded the average score of cognitively normal participants aged 50 to 64. The participant pool consisted of 1,623 SuperAgers, 8,829 individuals diagnosed with Alzheimer’s, and 7,628 cognitively normal controls.
Findings revealed that among non-Hispanic White participants, SuperAgers were 68 percent less likely to carry the APOE-ε4 variant compared to those with Alzheimer’s disease. They were also 19 percent less likely to possess the variant than age-matched cognitively normal controls. Additionally, non-Hispanic White SuperAgers showed a 103 percent higher likelihood of carrying the protective APOE-ε2 allele compared to Alzheimer’s participants, and a 28 percent higher likelihood than cognitively normal controls.
While the study included a smaller sample of non-Hispanic Black participants showing similar trends, the researchers emphasized the need for further studies with larger populations to assess whether resilience factors vary by demographic.
The implications of these findings suggest that SuperAgers may not simply be fortunate; rather, their genetic profiles play a significant role in their cognitive longevity. “This is by far the largest study to date to identify differences in APOE-ε4 allele frequency based on Superager status,” Gaynor stated. “We expect these findings to spark further interest in understanding how these genetic variants influence the development of clinical dementia due to Alzheimer’s disease.”
The research has been published in the journal Alzheimer’s & Dementia, marking a significant advancement in the understanding of aging and cognitive resilience. As interest in SuperAgers continues to grow, these findings may pave the way for new strategies aimed at enhancing cognitive health in aging populations.
